Full Press Release Details
Female Health Company Confirms Guidance for FY
November 6, 2008- The
Female Health Company (AMEX: FHC
which manufactures and markets the FC and
FC2 Female Condoms , today
confirmed its guidance for the fiscal year ended September 30,
very pleased to confirm that our August 2008 guidance regarding fiscal year
growth in units and pre-tax income was on target." noted O.B. Parrish, Chief
Executive Officer of The Female Health Company. "Growing global
acceptance of the female condom as the only available FDA approved barrier
contraceptive method controlled by women that provides protection against
HIV/AIDS is the basis for our growth. The FC Female Condom is now
available in over 100 countries, and we believe it will play an increasingly
important role in the global battle against HIV/AIDS in the
August 2008, we confirmed our previous sales guidance of 20% to 25% growth
units over the fiscal year 2007 level of 25.9 million units. At that time,
increased the pretax income guidance to be an increase of 200% to 250% over
FY2007 pre-tax income of $868,913. We now reaffirm that
are optimistic regarding the outlook for The Female Health
Company. Our team members are now working with organizations in
nearly all regions of the world, from Brazil to Cambodia, from the United
Kingdom to India, from New York to South Africa. Given the gravity of
the HIV/AIDS pandemic, our results are an indicator of the even greater
contribution the female condom will make to world health in coming years,"
The Female Health Company
Female Health Company (FHC), headquartered in Chicago, IL, is the maker of
FC Female Condom (FC1
and FC2), a revolutionary
offering women dual protection against both sexually transmitted diseases,
including HIV/AIDS, and unintended pregnancy. FHC was created as a worldwide
company in February 1996 with the purchase of Chartex Resources Ltd., the holder
of exclusive worldwide rights to FC1. The Company holds
exclusive product and technology patents for FC1 in the United States,
Australia, Brazil, Canada, France, Germany, Italy, Spain, the United Kingdom,
Republic of China, South Korea and Japan. Patents are pending for FC2. FHC is the sole manufacturer
and marketer of the FC1 and FC2
condoms in the world.
Female Health Company and its partners currently market the Female Condom under
FC Female Condom , FC2 Female
Condom , Reality , Femidom , Femy , and Care in the rest
information about the Female Health Company visit the Company's website at
. If you would like to be added to the Company's e-mail alert list, please
an e-mail to FHCInvestor@femalehealthcompany.com
Harbor" statement under the Private Securities Litigation Reform Act of
statements in this release which are not historical fact are "forward-looking
statements" as that term is defined in the Private Securities Litigation Reform
Act of 1995. Forward-looking statements in this release include the
Company's financial guidance for fiscal 2008. These statements are
based upon the Company's current plans and strategies, and reflect the Company's
current assessment of the risks and uncertainties related to its business,
are made as of the date of this release. The Company assumes no
obligation to update any forward-looking statements contained in this release
a result of new information or future events, developments or
circumstances. Such forward-looking statements are inherently subject
to known and unknown risks and uncertainties. The Company's actual results
future developments could differ materially from the results or developments
expressed in, or implied by, these forward-looking
statements. Factors that may cause actual results to differ
materially from those contemplated by such forward-looking statements include,
but are not limited to, the following: product demand and market acceptance;
competition in the Company's markets and the risk of new competitors and new
competitive product introductions; the Company's reliance on its international
partners in the consumer sector and on the level of spending on the female
condom by country governments, global donors and other public health
organizations in the global public sector; the economic and business environment
and the impact of government pressures; risks involved in doing business on
international level, including currency risks, regulatory requirements,
political risks, export restrictions and other trade barriers; the Company's
production capacity; efficiency and supply constraints; and other risks detailed
in the Company's press releases, shareholder communication and Securities and
Exchange Commission filings, including the Company's Form 10-KSB for the fiscal
year ended September 30, 2007. Actual events affecting the Company and the
impact of such events on the Company's operations may vary from those currently